The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis

Abstract

Objective: The clinical implications of B7H1 and B7H4 in pancreatic cancer have been described however, the prognostic significance of these genes in pancreatic cancer patients remains inconclusive. The aim of the present study was to evaluate the prognostic role of B7H1 and B7H4 in pancreatic cancer patients. Methods: Electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched for relevant articles published before May 2019. Meta-analyses were performed by pooling the hazard ratios (HRs) between overall survival or cancer-specific survival and high or low expression of B7H1/B7H4 in pancreatic cancer patients. Subgroup and sensitivity analyses were performed, and sources of variabilities were explored by performing meta-regression. Results: Sixteen studies (1434 patients’ data) were included. Compared with low expression, high expression of B7H1 was associated with significantly poor overall survival (HR 1.92 (95% confidence interval (CI) 1.35, 2.74); P<0.001) and cancer-specific survival (HR 2.46 (95% CI 1.55, 3.90); P<0.001). High expression of B7H4 also predicted poor overall survival (HR 2.38 (95% CI 1.89, 3.00); P<0.001). In subgroup analyses, a significant association between B7H1 and overall survival was observed for trials conducted in China (HR 2.08 (95% CI 1.29, 3.34)) but not in Japan (HR 1.98 (95% CI 1.33, 2.96)); or in studies with <50% patients having high expression (HR 2.02 (95% CI 1.40, 2.91)) but not in studies with >50% patients with high expression (HR 1.40 (95% CI 0.87, 2.26)). Conclusion: The current study suggests that high B7H1 and B7H4 expression is associated with a poor prognosis in pancreatic cancer patients.

Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients

“…Surgical resection is the only curative approach for pancreatic cancer and is feasible in 15% of the cases [ 4 ]. However, even for patients with operable pancreatic cancer, the 5-year survival rate is only 18%–24% [ 5 ]. One of the major reasons for the poor prognosis is the lack of effective biomarkers [ 4 ]; therefore, identification of novel prognostic markers is pivotal for better management of patients with pancreatic cancer.…”

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

“…In the past, many prognostic factors have been identified and considered, such as hemoglobin level, tumor burden, liver metastases, venous thromboembolism, baseline expression of B7H1 or B7H4, and baseline CA19-9 [17][18][19][20][21][22][23]. One of the most significant prognostic factors is baseline ECOG PS.…”

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands

“…120 Recent studies indicated the broad spectrum of patients' tumors that have been associated with aberrant B7-H4 expression across a wide variety of cancers, including colorectal, craniopharyngioma, RCC, BC, prostate cancer, pancreatic cancer, esophageal squamous cell carcinoma (ESCC), and cervical cancer. [137][138][139][140][141][142][143][144] Furthermore, serum sB7-H4 may be a valuable prognostic marker in patients in this wide spectrum of cancers. In patients with non-metastatic ccRCC, the high levels of sB7-H4 along with elevated PB neutrophil count were associated with either poor progression-free survival (PFS) or OS.…”